Evaluation of Saccharomyces Boulardii Combined With Standard Quadruple Therapy for Eradication of Helicobacter Pylori

• Status: Completed
• Trial end date: 2020-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The eradication rate of standard quadruple therapy has become less successful due to low compliance and high resistance to the antibiotics. Therefore, it is necessary to develop new treatment strategies that increase the eradication rate and reduce adverse effects. The aims of this prospective study is to investigate the efficacy of Saccharomyces Boulardii sachets for eradication of Hp, compared with standard quadruple therap.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Huazhong University of Science and Technology
• Collaborators: Anlu Puai Hospital; Hubei Aerospace Hospital; The third people's Hospital of Hubei Province; Wuhan Pu-Ai Hospital; Wuhan Union Hospital, China; Wuhan University; Xiaogan Central Hospital; Xiaogan First People's Hospital
• Treatments: Amoxicillin; Bismuth; Citric Acid; Clarithromycin; Esomeprazole; Potassium Citrate

Criteria

Inclusion Criteria:

• Helicobacter pylori infected patients

• 13C DOB>8

• age 22~65

Exclusion Criteria:

• prior Hp eradication therapy including amoxicillin and clarithromycin

• previous gastric resection

• allergic to the drugs used in this study

• previous use of proton pump inhibitors, bismuth, H2 receptor antagonist or antibiotics, probiotics within 4 weeks of the study

• Patients who were pregnant or lactating

• Patients taking NSAIDs, alcoholic or with other serious disease (e.g. hepatopathy, heart disease, nephropathy，diabete mellitus, hypertension…) effect the evaluation of this study

• Can't express the complaint correctly